Revisiting the arthritogenic peptide theory: Quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 702-713

  Schittenhelm, Ralf B ^a   Sian, Terry C C Lim Kam ^a   Wilmann, Pascal G ^a   Dudek, Nadine L ^a   Purcell, Anthony W ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; AMINO ACID; PROTEIN BINDING;

ALLELE; ALLOTYPE; AMINO ACID COMPOSITION; ARTICLE; CELLULAR IMMUNITY; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; CELL LINE; GENETICS; HUMAN; METABOLISM;

ALLELES; AMINO ACIDS; CELL LINE; HLA-B27 ANTIGEN; HUMANS; PEPTIDES; PROTEIN BINDING; TANDEM MASS SPECTROMETRY;

EID: 84923611798     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38963     Document Type: Article

References (52)

1. Breban M, Miceli-Richard C, Zinovieva E, Monnet D, Said-Nahal R,. The genetics of spondyloarthropathies. Joint Bone Spine 2006; 73: 355-62.
2. Vegvari A, Szabo Z, Szanto S, Glant TT, Mikecz K, Szekanecz Z,. The genetic background of ankylosing spondylitis. Joint Bone Spine 2009; 76: 623-8.
3. Chatzikyriakidou A, Voulgari PV, Drosos AA,. What is the role of HLA-B27 in spondyloarthropathies? Autoimmun Rev 2011; 10: 464-8.
4. Benjamin R, Parham P,. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990; 11: 137-42.
5. Hermann E, Yu DT, Meyer zum, Buschenfelde KH, Fleischer B,. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993; 342: 646-50.
6. Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005; 52: 892-901.
7. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, Lopez de Castro JA,. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002; 277: 37573-81.
8. Fiorillo MT, Ruckert C, Hulsmeyer M, Sorrentino R, Saenger W, Ziegler A, et al. Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes. J Biol Chem 2005; 280: 2962-71.
9. Cragnolini JJ, de Castro JA,. Identification of endogenously presented peptides from Chlamydia trachomatis with high homology to human proteins and to a natural self-ligand of HLA-B27. Mol Cell Proteomics 2008; 7: 170-80.
10. Cragnolini JJ, Garcia-Medel N, de Castro JA,. Endogenous processing and presentation of T-cell epitopes from Chlamydia trachomatis with relevance in HLA-B27-associated reactive arthritis. Mol Cell Proteomics 2009; 8: 1850-9.
11. Ben Dror L, Barnea E, Beer I, Mann M, Admon A,. The HLA-B2705 peptidome. Arthritis Rheum 2010; 62: 420-9.
12. Alvarez-Navarro C, Cragnolini JJ, Dos Santos HG, Barnea E, Admon A, Morreale A, et al. Novel HLA-B27-restricted epitopes from Chlamydia trachomatis generated upon endogenous processing of bacterial proteins suggest a role of molecular mimicry in reactive arthritis. J Biol Chem 2013; 288: 25810-25.
13. Lopez de Castro JA,. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 2007; 108: 27-33.
14. Khan MA, Mathieu A, Sorrentino R, Akkoc N,. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 2007; 6: 183-9.
15. Khan MA,. Polymorphism of HLA-B27: 105 subtypes currently known. Curr Rheumatol Rep 2013; 15: 362.
16. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC,. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989; 342: 692-6.
17. Lopez-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995; 45: 169-76.
18. D'Amato M, Fiorillo MT, Galeazzi M, Martinetti M, Amoroso A, Sorrentino R,. Frequency of the new HLA-B2709 allele in ankylosing spondylitis patients and healthy individuals. Dis Markers 1995; 12: 215-7.
19. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH,. Possible protective role of HLA-B2706 for ankylosing spondylitis. Tissue Antigens 1997; 49: 67-9.
20. Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997; 24: 1111-4.
21. Paladini F, Taccari E, Fiorillo MT, Cauli A, Passiu G, Mathieu A, et al. Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis Rheum 2005; 52: 3319-21.
22. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Appella E, et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997; 27: 368-73.
23. Garcia F, Marina A, Lopez de Castro JA,. Lack of carboxyl-terminal tyrosine distinguishes the B2706-bound peptide repertoire from those of B2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 1997; 49 (Pt 1): 215-21.
24. Griffin TA, Yuan J, Friede T, Stevanovic S, Ariyoshi K, Rowland-Jones SL, et al. Naturally occurring A pocket polymorphism in HLA-B2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. J Immunol 1997; 159: 4887-97.
25. Tieng V, Dulphy N, Boisgerault F, Tamouza R, Charron D, Toubert A,. HLA-B2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 1997; 47: 103-5.
26. Ramos M, Paradela A, Vazquez M, Marina A, Vazquez J, Lopez de Castro JA,. Differential association of HLA-B2705 and B2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability. J Biol Chem 2002; 277: 28749-56.
27. Gomez P, Montserrat V, Marcilla M, Paradela A, de Castro JA,. B2707 differs in peptide specificity from B2705 and B2704 as much as from HLA-B27 subtypes not associated to spondyloarthritis. Eur J Immunol 2006; 36: 1867-81.
28. Tan CT, Croft NP, Dudek NL, Williamson NA, Purcell AW,. Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 2011; 11: 2336-40.
29. Croft NP, Smith SA, Wong YC, Tan CT, Dudek NL, Flesch IE, et al. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog 2013; 9: e1003129.
30. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486: 554-8.
31. Schittenhelm RB, Dudek NL, Croft NP, Ramarathinam SH, Purcell AW,. A comprehensive analysis of constitutive naturally processed and presented HLA-C04:01 (Cw4)-specific peptides. Tissue Antigens 2014; 83: 174-9.
32. Lopez de Castro JA, Alvarez I, Marcilla M, Paradela A, Ramos M, Sesma L, et al. HLA-B27: a registry of constitutive peptide ligands. Tissue Antigens 2004; 63: 424-45.
33. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010; 26: 966-8.
34. Fissolo N, Haag S, de Graaf KL, Drews O, Stevanovic S, Rammensee HG, et al. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol Cell Proteomics 2009; 8: 2090-101.
35. Scull KE, Dudek NL, Corbett AJ, Ramarathinam SH, Gorasia DG, Williamson NA, et al. Secreted HLA recapitulates the immunopeptidome and allows in-depth coverage of HLA A02:01 ligands. Mol Immunol 2012; 51: 136-42.
36. Dudek NL, Tan CT, Gorasia DG, Croft NP, Illing PT, Purcell AW,. Constitutive and inflammatory immunopeptidome of pancreatic beta-cells. Diabetes 2012; 61: 3018-25.
37. Madden DR, Gorga JC, Strominger JL, Wiley DC,. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353: 321-5.
38. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC,. Identification of self peptides bound to purified HLA-B27. Nature 1991; 353: 326-9.
39. Madden DR, Gorga JC, Strominger JL, Wiley DC,. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70: 1035-48.
40. Alvarez I, Marti M, Vazquez J, Camafeita E, Ogueta S, Lopez de Castro JA,. The Cys-67 residue of HLA-B27 influences cell surface stability, peptide specificity, and T-cell antigen presentation. J Biol Chem 2001; 276: 48740-7.
41. Infantes S, Lorente E, Barnea E, Beer I, Barriga A, Lasala F, et al. Natural HLA-B2705 protein ligands with glutamine as anchor motif: implications for HLA-B27 association with spondyloarthropathy. J Biol Chem 2013; 288: 10882-9.
42. Collins EJ, Garboczi DN, Wiley DC,. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994; 371: 626-9.
43. Probst-Kepper M, Hecht HJ, Herrmann H, Janke V, Ocklenburg F, Klempnauer J, et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B3501. J Immunol 2004; 173: 5610-6.
44. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, Kostenko L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007; 8: 268-76.
45. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25: 3199-201.
46. Liebler DC, Zimmerman LJ,. Targeted quantitation of proteins by mass spectrometry. Biochemistry 2013; 52: 3797-806.
47. Colmegna I, Cuchacovich R, Espinoza LR,. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004; 17: 348-69.
48. Chen L, Fischer R, Peng Y, Reeves E, McHugh K, Ternette N, et al. Critical role of endoplasmic reticulum aminopeptidase 1 in determining the length and sequence of peptides bound and presented by HLA-B27. Arthritis Rheumatol 2014; 66: 284-94.
49. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 2005; 6: 689-97.
50. Sesma L, Montserrat V, Lamas JR, Marina A, Vazquez J, Lopez de Castro JA,. The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B2704 and B2706) differ by specific changes at three anchor positions. J Biol Chem 2002; 277: 16744-9.
51. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA,. Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B2703. Immunity 1994; 1: 121-30.
52. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG,. Dominant aromatic/aliphatic C-terminal anchor in HLA-B2702 and B2705 peptide motifs. Immunogenetics 1994; 39: 74-7.